论文部分内容阅读
在Vitk 缺乏或接受Vitk 拮抗剂患者的血液中发现脱-γ-碳氧凝血酶原(DCP)。作者应用Naraki等新近建立的测定DCP 双抗体夹心法EIA 对91例肝细胞肌癌患者和其它肝胆疾病测定血浆DCP 水平。190例患者,男136例、女54例。其中肝细胞癌91例、肝硬变24例、胆管癌20例(6例胆管细胞癌、5例胆囊癌和9例胆管癌)、7例十二指肠乳头状癌、27例胰腺癌、11例胆石症和10例各种其它良恶性病变。3.8%枸橼酸钠抗凝静脉血立即离心分离血清贮于-20℃待测。用特异性单克隆抗体EIA 法测定血浆DCP 浓度。血浆DCP 正常范围<0.1AV/mL(1AU/mL=1μg/mL 纯凝血酶原),血清AFP 水平用AFP-EIA 法测定,血浆Vitk 水平用HPLC(高度
De-gamma-carmectin (DCP) was found in the blood of Vitk-deficient or Vitk antagonist patients. The authors used Naraki and other newly established DCP double antibody sandwich ELISA EIA in 91 patients with hepatocellular carcinoma and other liver and gallbladder disease determination of plasma DCP levels. 190 patients, 136 males and 54 females. Among them, there were 91 cases of hepatocellular carcinoma, 24 cases of cirrhosis, 20 cases of cholangiocarcinoma (6 cases of cholangiocarcinoma, 5 cases of gallbladder carcinoma and 9 cases of cholangiocarcinoma), 7 cases of duodenal papillary carcinoma, 27 cases of pancreatic cancer, 11 cases of cholelithiasis and 10 cases of various other benign and malignant lesions. 3.8% sodium citrate anticoagulated venous immediately centrifuged serum stored at -20 ℃ to be tested. Plasma DCP concentration was measured by specific monoclonal antibody EIA method. Plasma DCP normal range <0.1AV / mL (1AU / mL = 1μg / mL pure prothrombin), serum AFP levels by AFP-EIA method, plasma Vitk levels by HPLC